Resmetirom's FDA approval offers a liver-specific therapy, reducing hepatic fat and fibrosis, potentially improving patient outcomes and lowering care costs. Resmetirom offers a targeted approach ...

Its lead candidate resmetirom met its primary and secondary objectives in the trial, which involved patients with non-alcoholic fatty liver disease (NAFLD) including some with presumed NASH ...

The Massachusetts company has reported the results of the phase 3 MAESTRO-NASH trial of resmetirom – a once daily, oral, thyroid hormone receptor (THR) β-selective agonist – showing that it ...

marking a pivotal year highlighted by the FDA approval and successful launch of Rezdiffra (resmetirom). Rezdiffra, the first and only approved therapy for MASH (metabolic dysfunction-associated ...

Resmetirom significantly reduced liver stiffness in patients with compensated MASH cirrhosis, with a 6.7 kPa decrease over 2 years. The reduction in liver stiffness may lower the risk of liver ...

demonstrating the potential of Rezdiffra (resmetirom) to significantly reduce liver stiffness in patients with compensated MASH cirrhosis (F4c), a critical marker for liver disease progression.